SI-BONE, Inc. (NASDAQ:SIBN) Shares Acquired by Lisanti Capital Growth LLC

Lisanti Capital Growth LLC raised its position in SI-BONE, Inc. (NASDAQ:SIBN) by 51.2% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 51,915 shares of the company’s stock after buying an additional 17,585 shares during the period. Lisanti Capital Growth LLC owned approximately 0.13% of SI-BONE worth $1,090,000 at the end of the most recent quarter.

Other large investors also recently modified their holdings of the company. RiverPark Advisors LLC boosted its holdings in SI-BONE by 22.6% in the fourth quarter. RiverPark Advisors LLC now owns 3,151 shares of the company’s stock valued at $66,000 after purchasing an additional 580 shares during the last quarter. Amalgamated Bank boosted its stake in shares of SI-BONE by 12.9% during the 4th quarter. Amalgamated Bank now owns 5,877 shares of the company’s stock valued at $123,000 after buying an additional 673 shares during the last quarter. Arizona State Retirement System grew its position in shares of SI-BONE by 7.7% during the fourth quarter. Arizona State Retirement System now owns 10,675 shares of the company’s stock worth $224,000 after buying an additional 762 shares in the last quarter. Swiss National Bank increased its stake in shares of SI-BONE by 1.1% in the third quarter. Swiss National Bank now owns 76,600 shares of the company’s stock worth $1,627,000 after buying an additional 800 shares during the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in SI-BONE by 14.9% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 8,541 shares of the company’s stock valued at $179,000 after acquiring an additional 1,106 shares in the last quarter. 98.11% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at SI-BONE

In related news, insider Anthony J. Recupero sold 3,307 shares of SI-BONE stock in a transaction dated Tuesday, April 2nd. The shares were sold at an average price of $15.50, for a total transaction of $51,258.50. Following the sale, the insider now directly owns 252,453 shares in the company, valued at $3,913,021.50. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. In other news, CFO Anshul Maheshwari sold 2,425 shares of the business’s stock in a transaction on Tuesday, April 2nd. The stock was sold at an average price of $15.45, for a total value of $37,466.25. Following the sale, the chief financial officer now owns 205,516 shares of the company’s stock, valued at approximately $3,175,222.20. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Anthony J. Recupero sold 3,307 shares of the company’s stock in a transaction on Tuesday, April 2nd. The shares were sold at an average price of $15.50, for a total value of $51,258.50. Following the completion of the sale, the insider now owns 252,453 shares of the company’s stock, valued at approximately $3,913,021.50. The disclosure for this sale can be found here. Over the last quarter, insiders sold 11,905 shares of company stock valued at $190,273. 5.40% of the stock is currently owned by corporate insiders.

SI-BONE Stock Performance

Shares of SIBN stock traded up $1.20 during trading hours on Tuesday, reaching $15.68. The stock had a trading volume of 595,426 shares, compared to its average volume of 432,549. The company has a debt-to-equity ratio of 0.21, a current ratio of 9.01 and a quick ratio of 8.15. The firm has a 50-day simple moving average of $15.87 and a 200-day simple moving average of $18.02. The firm has a market capitalization of $646.02 million, a PE ratio of -13.54 and a beta of 1.24. SI-BONE, Inc. has a twelve month low of $13.96 and a twelve month high of $29.51.

SI-BONE (NASDAQ:SIBN) last released its quarterly earnings results on Monday, February 26th. The company reported ($0.27) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.29) by $0.02. SI-BONE had a negative return on equity of 28.22% and a negative net margin of 31.20%. The company had revenue of $38.86 million for the quarter, compared to analysts’ expectations of $38.60 million. As a group, equities analysts forecast that SI-BONE, Inc. will post -0.98 earnings per share for the current year.

Analysts Set New Price Targets

Several research analysts have weighed in on SIBN shares. Piper Sandler started coverage on shares of SI-BONE in a report on Thursday, March 28th. They set an “overweight” rating and a $25.00 price objective for the company. Truist Financial restated a “buy” rating and set a $24.00 price objective (down from $26.00) on shares of SI-BONE in a research note on Tuesday, February 27th. Morgan Stanley lowered their target price on shares of SI-BONE from $26.00 to $25.00 and set an “overweight” rating for the company in a research note on Tuesday. JMP Securities restated a “market outperform” rating and issued a $32.00 price target on shares of SI-BONE in a research report on Tuesday. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $27.00 price objective on shares of SI-BONE in a research report on Tuesday. Six research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock has a consensus rating of “Buy” and an average price target of $27.29.

About SI-BONE

SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.